Resverlogix Corp. Announces Favorable Results From Toxicology Studies

CALGARY, ALBERTA --Resverlogix Corp. (“Resverlogix”) (TSX: RVX) is pleased to announce today favorable results from 28-day toxicology studies conducted on its lead drug compound RVX-208. With the completion of this critical component of the drug development program for RVX-208, the focus will shift toward completion of an Investigational New Drug (IND) application to support clinical development.

“As part of our preparations for human clinical trials, we have characterized important aspects of the efficacy and safety of RVX-208,” stated Dr. Gregory S. Wagner, Ph.D., Senior Vice President Preclinical Development, Resverlogix. “The pharmacology data collected during a three week study in mice indicate that the efficacy progressively increased with the duration of treatment, thus making the molecule attractive for chronic therapy. The 28-day toxicity studies conducted in rats and monkeys indicate that high doses of RVX-208 are safe and well tolerated on repeated oral administration. These combined findings confirm the positioning of RVX-208 as a novel therapeutic agent designed to positively regulate levels of Apolipoprotein A-1 (ApoA-I) and HDL, along with a significant margin of safety.” Dr. Wagner added further, “With these data in hand we will now focus on completing our IND program and initiation of the Phase I clinical program for RVX-208.”

“We are very pleased with the speed and the results of the IND enabling studies and clinical preparations for RVX-208,” said Dr. Jan Johansson, M.D., Ph.D., Senior Vice President Clinical Affairs, Resverlogix. “ApoA-I enhancement via novel small molecules represents the next major paradigm in reducing cardiovascular risk. The recent efficacy and safety results of RVX-208 position this molecule as a leading drug candidate to meet the great unmet medical need to stabilize and regress atherosclerosis.”

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company in the development of novel therapies for important global medical markets with significant unmet medical needs. The Company’s primary focus is to conduct leading research, development and commercialization of novel therapeutics that address the main underlying cause of cardiovascular disease (CVD). The Company’s secondary focus is TGF-Beta Shield™, a program that aims to address the unmet medical needs of burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies for the treatment of unmet human diseases. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX: RVX). For further information, please visit our web site at www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.